TRUMENBA safety information
Scroll for Important Safety Information and Indication
IMPORTANT SAFETY INFORMATION
- Severe allergic reaction after a previous dose of Trumenba is a contraindication
- Individuals with altered immunocompetence may have reduced immune responses to Trumenba
- As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
- In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%). Nausea was reported in up to 24% of adolescents in early phase studies
- Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
- Safety and effectiveness have not been established in pregnant women
- Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
- The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed
Please see full Prescribing Information.
TRUMENBA in your practice
The science behind TRUMENBA
TRUMENBA clinical studies
*Advisory Committee on Immunization Practices.
- Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; 2017.
- MacNeil JR, Rubin L, Folaranmi T, et al. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015;64(41):1171-1176.
- McNeil LK, Murphy E, Zhao XJ, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine. 2009;27(25-26):3417-3421.